You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PRRT

Showing 1 - 25 of 80
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Neuroendocrine Tumor, Pancreas Cancer Trial in Chicago (cytoreductive surgery, Lutathera - a small molecule used in

Not yet recruiting
  • Pancreatic Neuroendocrine Tumor
  • Pancreas Cancer
  • cytoreductive surgery
  • +2 more
  • Chicago, Illinois
    The University of Chicago
Nov 8, 2022

Pancreatic Neuroendocrine Tumor Trial in Milano (peptide receptor radionuclide therapy with Y-90-DOTATOC)

Recruiting
  • Pancreatic Neuroendocrine Tumor
  • peptide receptor radionuclide therapy with Y-90-DOTATOC
  • Milano, Italy
  • +1 more
Sep 30, 2022

Advanced Pancreatic Cancer and Cholangiocarcinoma Trial in Hangzhou (PRRT with 177Lu-EB-FAPI)

Recruiting
  • Advanced Pancreatic Cancer and Cholangiocarcinoma
  • PRRT with 177Lu-EB-FAPI
  • Hangzhou, Zhejiang, China
    First Affiliated Hospital of Zhejiang University
Oct 10, 2023

Neuroblastoma Trial in Lille, Lyon, Toulouse (PRRT with 177Lu-DOTATATE)

Not yet recruiting
  • Neuroblastoma
  • PRRT with 177Lu-DOTATATE
  • Lille, France
  • +2 more
Nov 8, 2022

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Completed
  • Radiation Nephropathy
    • (no location specified)
    Mar 22, 2023

    Merkel Cell Carcinoma Trial (Pembrolizumab, Lutetium Lu 177 dotatate)

    Not yet recruiting
    • Merkel Cell Carcinoma
    • (no location specified)
    Oct 12, 2022

    Neuroendocrine Tumors, Meningioma, Neuroblastoma Trial in Iowa City (radiation, diagnostic test, drug)

    Active, not recruiting
    • Neuroendocrine Tumors
    • +3 more
    • 90Y-DOTA tyr3-Octreotide
    • +2 more
    • Iowa City, Iowa
      University of Iowa Hospitals and Clinics
    Oct 6, 2022

    HRQoL During PRRT in Patients With NETs

    Completed
    • Neuroendocrine Tumors
    • +2 more
      • (no location specified)
      Jun 16, 2022

      Gastroenteropancreatic Neuroendocrine Tumor Trial in Stanford (Lutathera, Gallium 68 Dotatate, Computed Tomography (CT))

      Suspended
      • Gastroenteropancreatic Neuroendocrine Tumor
      • Stanford, California
        Stanford Cancer Institute Palo Alto
      Sep 21, 2022

      Neuroendocrine Tumors Trial in Houston (AlphaMedix)

      Recruiting
      • Neuroendocrine Tumors
      • Houston, Texas
        Excel Diagnostics and Nuclear Oncology Center
      Jan 5, 2022

      Neuroendocrine Tumors Trial in Iowa City ([90]Y-DOTATOC)

      Suspended
      • Neuroendocrine Tumors
      • Iowa City, Iowa
        The Holden Comprehensive Cancer Center
      Mar 8, 2022

      (PRRT) for the Treatment of Neuroendocrine Tumors

      Enrolling by invitation
      • Neuroendocrine Tumors
      • Peptide Receptor Radionuclide Therapy
      • Dallas, Texas
        Methodist Dallas Medical Center
      Oct 27, 2021

      Neuroendocrine Tumor Trial in Aarhus (Lu-177-DOTA-Octreotide)

      Recruiting
      • Neuroendocrine Neoplasm
      • Aarhus, Palle Juul-Jensens Boulevard, Denmark
        Aarhus University Hospital, department of Nuclear medicine and P
      Jun 7, 2021

      Neuroendocrine Tumors Trial in Melbourne (Talazoparib)

      Recruiting
      • Neuroendocrine Tumors
      • Melbourne, Victoria, Australia
        Peter MacCallum Cancer Centre
      Sep 20, 2021

      Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

      Not yet recruiting
      • Digestive System Neuroendocrine Tumor G1
      • +5 more
      • Tumor Debulking
      • +5 more
      • Nashville, Tennessee
        Vanderbilt University/Ingram Cancer Center
      Aug 23, 2023

      Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant Trial in Saint Louis (temporally-modulated pulsed radiotherapy (TMPRT))

      Recruiting
      • Astrocytoma
      • +2 more
      • temporally-modulated pulsed radiotherapy (TMPRT)
      • Saint Louis, Missouri
        Washington University School of Medicine
      Jan 19, 2023

      Gastro-entero-pancreatic Neuroendocrine Tumors Trial in Meldola (Capecitabine, Lu-PRRT, SS-LAR)

      Active, not recruiting
      • Gastro-entero-pancreatic Neuroendocrine Tumors
      • Meldola, FC, Italy
        Irst Irccs
      Feb 25, 2021

      Lung Neuroendocrine Tumor, GEP Neuroendocrine Tumor Trial in Naples (Cabozantinib and Temozolomide)

      Recruiting
      • Lung Neuroendocrine Neoplasm
      • GEP Neuroendocrine Tumor
      • Cabozantinib and Temozolomide
      • Naples, Campania, Italy
        National Cancer Institute of Naples
      Oct 12, 2021

      Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor Trial (procedure, drug, other)

      Not yet recruiting
      • Metastatic Midgut Neuroendocrine Tumor
      • Unresectable Midgut Neuroendocrine Tumor
      • Biospecimen Collection
      • +5 more
      • (no location specified)
      Mar 16, 2023

      Metastatic Malignant Tumor in the Liver, Neuroendocrine Tumor Trial in San Francisco (procedure, biological, device)

      Recruiting
      • Metastatic Malignant Neoplasm in the Liver
      • Neuroendocrine Neoplasm
      • Arterial Embolization
      • +3 more
      • San Francisco, California
        University of California, San Francisco
      Dec 22, 2022

      Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea Trial in Iowa City (Telotristat ethyl, Peptide Receptor Radionuclide

      Withdrawn
      • Neuroendocrine Tumors
      • +2 more
      • Telotristat ethyl
      • +2 more
      • Iowa City, Iowa
        University of Iowa Hospital and Clinics
      Feb 9, 2022

      Neuroendocrine Tumors Trial in Portland (Cabozantinib, Lu-177)

      Not yet recruiting
      • Neuroendocrine Tumors
      • Portland, Oregon
        Providence Portland Cancer Institute - Franz Clinic
      Feb 10, 2022

      Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma Trial (Lutetium Lu 177 Dotatate,

      Not yet recruiting
      • Metastatic Pancreatic Neuroendocrine Tumor
      • Unresectable Pancreatic Neuroendocrine Carcinoma
      • Lutetium Lu 177 Dotatate
      • +4 more
      • (no location specified)
      Feb 10, 2022

      Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT) Trial in Ferrara (Lutetium-177 (177Lu)-DOTATOC, Yttrium-90

      Recruiting
      • Neuroendocrine Tumors
      • Peptide Receptor Radionuclide Therapy (PRRT)
      • Lutetium-177 (177Lu)-DOTATOC
      • +4 more
      • Ferrara, Italy
        University Hospital of Ferrara
      Mar 5, 2021

      Neuroendocrine Tumors Trial in Meldola (177Lu-DOTATATE 25.9 GBq activity, 177Lu-DOTATATE 18.5 GBq activity)

      Active, not recruiting
      • Neuroendocrine Tumors
      • 177Lu-DOTATATE 25.9 GBq activity
      • 177Lu-DOTATATE 18.5 GBq activity
      • Meldola, FC, Italy
        Irst Irccs
      Feb 25, 2021